Key result
Aspirin added to labetalol cuts preeclampsia risk ~73% in pregnant women with chronic hypertension.
Why the study?
The study was conducted to investigate the effect of aspirin on pregnancy outcomes and serum levels of ET-1 and TM in pregnant patients with chronic hypertension.
Does the addition of aspirin to labetalol improve pregnancy outcomes and reduce serum ET-1 and TM levels in pregnant women with chronic hypertension?
RCT (n=120)
Open-label
Randomly divided
No
Does the addition of aspirin to labetalol improve pregnancy outcomes and reduce serum ET-1 and TM levels in pregnant women with chronic hypertension?
The addition of low-dose aspirin to labetalol in pregnant women with chronic hypertension significantly reduces blood pressure, improves endothelial markers (ET-1 and TM), and decreases the risk of preeclampsia and intrauterine growth retardation.
Supports adjunctive aspirin consideration in chronic hypertension pregnancies; leaves open need for randomized confirmation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2021) conducted an RCT in Chronic hypertension in pregnancy (n=120). Aspirin vs. Labetalol alone was evaluated on Incidence of preeclampsia (p=<0.001). The addition of aspirin to labetalol significantly reduced the incidence of preeclampsia (8.5% vs 31.6%, p<0.001) and lowered serum ET-1 and TM levels compared to labetalol alone in pregnant women with chronic hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: